Oral Health Group

February 2, 2011 News Decay assessment and prevention

Oragenics, Inc. Announces A Second Phase 1 Clinical Trial Of SMaRT™ Replacement Therapy

by ken

Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) announced its intention to commence a second phase 1 clinical trial of SMaRT Replacement Therapy. The Company has retained PRA International as the Clinical Research Organization (CRO) for clinical trials management services related…